Amgen third-quarter sales rise 5%, profit up before charge reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
An injected version of Eisai
and Biogen s Alzheimer s drug Leqembi works as
well as the current intravenous version at removing toxic brain
plaques, according to an analysis presented by Eisai.
A weekly shot form of Leqembi, given as two consecutive injections, could simplify use of the groundbreaking Alzheimer's treatment, potentially allowing patients to receive the drug at home instead of traveling to an infusion center twice a month. The Japanese drugmaker's review compared data for 72 patients with early Alzheimer's given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion.
By Julie Steenhuysen and Deena Beasley BOSTON (Reuters) - An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the curr.
Blood tests for Alzheimer's are needed to more widely diagnose the brain-wasting disease and understand its prevalence, but it will be another couple of years before they become an everyday tool, medical experts and company executives say. Blood testing is initially likely to be used to rule out Alzheimer's, with positive results signaling the need for more advanced diagnostics. Several Alzheimer's blood tests are in the works – and one is already being sold to consumers – but none have been established as accurate, formally approved by regulators or reimbursed by insurers.